Wednesday, 18. March 2015

IDT Biologika receiveds CMO Leadership Award for quality, reliability, productivity and innovation

IDT Biologika, a major contract manufacturer of biopharmaceuticals and vaccines, accepted a CMO Leadership Award for quality, reliability, productivity and innovation during a ceremomy held in New York City, March 18th. Sponsored by Life Science Leader, the awards recognize the top contract manufacturing companies serving the pharmaceutical and biopharmaceutical industries.

The annual awards are based on many of the same metrics pharmaceutical companies consider prior to selecting a contract manufacturer. Companies achieving scores within the top 10 percentile were recognized with a 2015 CMO Leadership Award.

Dr. Ralf Pfirmann accepted the 2015 CMO Leadership Award on behalf of IDT Biologika. „As IDT Biologika expands to serve an ever-larger customer base, more industry partners have come to recognize the depth of our capabilities,“ said Dr. Pfirmann. „I thank everyone for acknowleding IDT’s expertise in developing, manufacturing, packaging and managing vaccines and biopharmaceuticals in a way that significantly adds to the safety and credibility of our industry,“ he said.

Recognized for leadership in 4 of 5 key areas, IDT Biologika was among the highest rated biotech companies at the 2015 CMO Leadership Awards ceremony. „Being recognized for quality, reliability, productivity and innovation is a testament to IDT’s on-going investment in technical talent, infrastructure and automated product management systems. Just as importantly, it is a testament to our owner, the Klocke Group, who recognizes the extra value that comes with a long term commitment.“

IDT Biologika today offers its partner companies contract services that range from live vaccines and gene therapy to drug subtance manufacturing and antibody drug conjugates.

News Overview

Positive interim summary of strategic realignment at CPhl trade fair:

IDT Biologika Awarded new Task Order to Manufacture Vaccines and Biologics for Infectious Diseases

IDT Biologika inaugurates new multifunctional production facility for vaccines at BioPharmaPark area

Ceva completes acquisition

IDT Biologika to concentrate on human vaccines and pharmaceuticals

Ceva Santé Animale and IDT Biologika GmbH

CMO Leadership Awards 2019

IDT Biologika Awarded 10-Year NIH Contract

CEPI Awards Contract Worth Up To USD$36 million to Consortium led by IDT to Develop MERS Vaccine

25th anniversary of the privatization of IDT Biologika